ASCO 2020: DESTINY-Gastric01 trial reveals positive outlook for the treatment of HER2 positive gastric cancer patients with Enhertu

4th June 2020 (Last Updated June 4th, 2020 14:35)

At the virtual ASCO 2020 conference, an update on DESTINY-Gastric01 Phase II trial provided a positive outlook for the future therapy of gastric cancer patients with the drug Enhertu (trastuzumab deruxtecan).

Enhertu is an antibody-drug conjugate made up of the HER-2 targeting trastuzumab antibody attached to a topoisomerase inhibitor payload. Read more here.